Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Myriad Genetics (NASDAQ: MYGN), a molecular diagnostic testing and precision medicine company, has announced its participation in two major upcoming healthcare investor conferences. Management will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 6:00 PM ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 2:00 PM ET. Both presentations will be available for viewing through live and archived webcasts on the company's investor relations website at investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN), un'azienda specializzata in test diagnostici molecolari e medicina di precisione, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario. Il management parteciperà a una discussione informale durante la BofA Securities 2025 Health Care Conference il 14 maggio 2025 alle 18:00 ET, e alla Goldman Sachs 46th Annual Global Healthcare Conference l'11 giugno 2025 alle 14:00 ET. Entrambe le presentazioni saranno disponibili in diretta e in differita tramite webcast sul sito web dedicato agli investitori dell'azienda all'indirizzo investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN), una empresa especializada en pruebas diagnósticas moleculares y medicina de precisión, ha anunciado su participación en dos importantes conferencias para inversores en el sector sanitario. La dirección participará en una charla informal en la BofA Securities 2025 Health Care Conference el 14 de mayo de 2025 a las 6:00 PM ET, y en la Goldman Sachs 46th Annual Global Healthcare Conference el 11 de junio de 2025 a las 2:00 PM ET. Ambas presentaciones estarán disponibles para su visualización en transmisiones en vivo y archivos en el sitio web de relaciones con inversores de la compañía en investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN)는 분자 진단 검사 및 정밀 의학 회사로, 다가오는 두 주요 헬스케어 투자자 컨퍼런스에 참여한다고 발표했습니다. 경영진은 2025년 5월 14일 오후 6시(ET)에 열리는 BofA Securities 2025 Health Care Conference에서 파이어사이드 채팅에 참여하며, 2025년 6월 11일 오후 2시(ET)에 열리는 Goldman Sachs 46th Annual Global Healthcare Conference에도 참석할 예정입니다. 두 발표 모두 회사 투자자 관계 웹사이트 investor.myriad.com을 통해 생중계 및 아카이브 웹캐스트로 시청할 수 있습니다.
Myriad Genetics (NASDAQ : MYGN), une entreprise spécialisée dans les tests diagnostiques moléculaires et la médecine de précision, a annoncé sa participation à deux grandes conférences à venir pour les investisseurs du secteur de la santé. La direction participera à une discussion informelle lors de la BofA Securities 2025 Health Care Conference le 14 mai 2025 à 18h00 ET, ainsi qu'à la Goldman Sachs 46th Annual Global Healthcare Conference le 11 juin 2025 à 14h00 ET. Les deux présentations seront accessibles en direct et en replay via des webcasts sur le site des relations investisseurs de la société à l'adresse investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN), ein Unternehmen für molekulare Diagnostik und Präzisionsmedizin, hat seine Teilnahme an zwei bedeutenden bevorstehenden Gesundheitsinvestorenkonferenzen bekannt gegeben. Das Management wird am 14. Mai 2025 um 18:00 Uhr ET an einem Fireside-Chat auf der BofA Securities 2025 Health Care Conference teilnehmen und am 11. Juni 2025 um 14:00 Uhr ET an der Goldman Sachs 46th Annual Global Healthcare Conference. Beide Präsentationen werden live und als Archiv-Webcast auf der Investor-Relations-Website des Unternehmens unter investor.myriad.com verfügbar sein.
- None.
- None.
Correction: Time of BofA Conference
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences:
- The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.
- Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025.
Live and archived webcasts of all presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
When is Myriad Genetics (MYGN) presenting at the BofA Securities Healthcare Conference 2025?
What time is Myriad Genetics (MYGN) presenting at the Goldman Sachs Healthcare Conference 2025?
Where can I watch Myriad Genetics (MYGN) investor conference presentations?
Which investor healthcare conferences is Myriad Genetics (MYGN) attending in 2025?
